EUVIMEDEUVIMED entdecken
Crossref

A Sustained H 2 /Fluorouracil‐Releasing Suppository for High‐efficacy and Low‐Toxicity Hydrogenochemotherapy of Colon Cancer

Danyang Chen, Zuan Wu, Chao Xia, Haiyan Yang, Wenjiang Ding, Qianjun He iD

Advanced Healthcare Materials · 2025-03 · 14 (7)

DOI: 10.1002/adhm.202404054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 21.01.2025. Verfasst von Danyang Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Hydrogen Science & Center of Hydrogen Science, School of Materials Science and Engineering, Shanghai Jiao Tong University,…. Hauptthemen laut MEDLINE: Fluorouracil, Hydrogen, Colonic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Program, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To attenuate the intestinal toxicity of chemotherapeutic drugs from rectal suppositories and enhance their chemotherapeutic outcome is greatly significant, but maintains a challenge. In this work, a new strategy of local synergistic hydrogenochemotherapy is proposed to attenuate side effects and enhance therapeutic efficacy based on the anti‐cancer selectivity and normal cells‐protecting effect of H 2 , and construct a novel anti‐cancer formulation of rectal suppository (5‐FU/CSN@FAG) by fatty acid glycerides (FAG) encapsulating 5‐fluorouracil (5‐FU, a first‐line drug for colorectal cancer treatment) and cerium silicide nanoparticles (CSN) with a sustained hydrolytic H 2 release behavior which is synchronous with 5‐FU release. The 3‐week treatment with the suppository once a day can not only completely eradicate colon tumors without tumor recurrence after suppository administration withdrawal, but also efficiently protect the intestinal tract from chemotherapeutic damage. Mechanistically, H 2 generated by CSN reduces the toxicity of 5‐FU to normal cells in the intestinal tract by scavenging over‐expressed reactive oxygen species and correcting energy metabolism, and also assists 5‐FU to promote the apoptosis of colon tumor cells by inhibiting their respiration through a CO signaling pathway. High biosafety and therapeutic validity endow the developed suppository with a high potential for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluorouracilHydrogenColonic NeoplasmsAnimalsHumansSuppositoriesMiceNanoparticlesApoptosisCell Line, TumorMice, Inbred BALB CDelayed-Action Preparations

Stichwörter der Autor:innen

cancer therapycontrolled releasehydrogen therapynanomedicinesuppository

Substanzen

FluorouracilHydrogenSuppositoriesDelayed-Action Preparations

Autor:innen und Institutionen

  • Shanghai Key Laboratory of Hydrogen Science & Center of Hydrogen Science, School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Shenzhen Research Institute, Shanghai Jiao Tong University, Shenzhen, 518057, China.

ORCID-Profile: Qianjun He

Förderung

  • National Natural Science Foundation of China
  • Shenzhen Science and Technology Program
  • National Key Research and Development Program of China

Zitieren

APA

Chen, D., Wu, Z., Xia, C., Yang, H., Ding, W., & He, Q. (2025). A Sustained H 2 /Fluorouracil‐Releasing Suppository for High‐efficacy and Low‐Toxicity Hydrogenochemotherapy of Colon Cancer. Advanced Healthcare Materials, 14(7). https://doi.org/10.1002/adhm.202404054

Vancouver

Chen D, Wu Z, Xia C, Yang H, Ding W, He Q. A Sustained H 2 /Fluorouracil‐Releasing Suppository for High‐efficacy and Low‐Toxicity Hydrogenochemotherapy of Colon Cancer. Advanced Healthcare Materials. 2025;14(7). doi:10.1002/adhm.202404054

BibTeX
@article{Chen2025,
  author = {Chen, Danyang and Wu, Zuan and Xia, Chao and Yang, Haiyan and Ding, Wenjiang and He, Qianjun},
  title = {A Sustained H 2 /Fluorouracil‐Releasing Suppository for High‐efficacy and Low‐Toxicity Hydrogenochemotherapy of Colon Cancer},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  volume = {14},
  number = {7},
  doi = {10.1002/adhm.202404054}
}
Kostenlos starten →